

## 9. Bibliography and References Cited

- [1] Fabbro D, Cowan-Jacob SW, Möblitz H, Martiny-Baron G. Targeting cancer with small-molecular-weight kinase inhibitors. *Methods in Molecular Biology: Kinase Inhibitors*, 795:1–34, 2012.
- [2] Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. *Science*, 298:1912–1934, 2002.
- [3] Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis of kinase inhibitor selectivity. *Nature Biotech*, 26:127–132, 2008.
- [4] Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. *Structure*, 15:299–311, 2007.
- [5] Aleksandrov A, Simonson T. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. *J Biol Chem*, 285:13807–13815, 2010.
- [6] Lin YL, Meng Y, Jiang W, Roux B. Explaining why Gleevec is a potent inhibitor of Abl kinase. *Proc Natl Acad Sci USA*, 110:1664–1669, 2013.
- [7] et al JB. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity. *Nature*, 483:603–607, 2013.
- [8] Warmuth MK, Liao J, Rätech G, Mathieson M, Putta S, Lemmen C. Active learning with support vector machines in the drug discovery process. *J Chem Inf Comput Sci*, 43:667–673, 2003.
- [9] Pande VS, Beauchamp KA, Bowman GR. Everything you wanted to know about Markov state models but were afraid to ask. *Methods*, 52:99–105, 2010.
- [10] Prinz JH, Wu H, Sarich M, Keller B, Fischbach M, Held M, Chodera JD, Schütte C, Noé F. Markov models of molecular kinetics: Generation and validation. *J Chem Phys*, 134:174105, 2011.
- [11] Chodera JD, Mobley DL, Shirts MR, Dixon RW, Branson KM, Pande VS. Free energy methods in drug discovery and design: Progress and challenges. *Curr Opin Struct Biol*, 21:150, 2011.
- [12] Martin MP, Alam R, Betzi S, Ingles DJ, Zhu JY, Schönbrunn E. A novel approach to the discovery of small-molecule ligands of cdk2. *ChemBioChem*, 13(14):2128–2136, 2012.
- [13] Chambers SP, Austen DA, Fulghum JR, Kim WM. High-throughput screening for soluble recombinant expressed kinases in *Escherichia coli* and insect cells. *Protein Expression and Purification*, 36:40–47, 2004.
- [14] Wang L, Foster M, Zhang Y, Tschantz WR, Yang L, Worrall J, Loh C, Xu X. High yield expression of non-phosphorylated protein tyrosine kinases in insect cells. *Protein Express Pur*, 61:204–211, 2008.
- [15] Seeliger MA, Young M, Henderson MN, Pellicena P, King DS, Falick AM, Kuriyan J. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. *Protein Sci*, 14:3135–3139, 2005.
- [16] Levinson NM, Boxer SG. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. *PLoS One*, 7:e29828, 2012.